EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Past, present and future of nivolumab: new horizons in immuno-oncology

Inamul Hasan Madar, Sreeshma Ravindran Kammarambath

Frontiers in Oncology · 07.04.2026 · 16

DOI: 10.3389/fonc.2026.1801874 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 07.04.2026. Verfasst von Inamul Hasan Madar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Integrative Omics Data Science (CIODS), Yenepoya (Deemed to be University), Mangalore, Karnataka, India. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the last two years, nivolumab (an inhibitor of programmed death-protein 1, PD-1) has established itself as a cornerstone of modern-day cancer immunotherapy. The immuno-oncology field is developing at an accelerated rate, as nivolumab is progressively acting as an optimally strategic, globally diffused treatment base across a heterogeneous spectrum of malignancies. This has been driven by the accruing data on pivotal phase 3 trials that show better survival rates alongside subsequent regulatory approvals both at the national and international levels that have expanded its therapeutic indications. Meanwhile its translational and clinical impact has been increased further by expanded-access programmes and new combinatorial approaches. All these developments highlight the increasing clinical relevance of nivolumab as they also highlight the current issues in the provision of equitable access, in performing biomarker-based patient stratification, and in optimizing therapeutic sequencing in the rapidly evolving framework of precision oncology.

Schlagwörter

Stichwörter der Autor:innen

FDAPD-1biosimilarcancernivolumab

Autor:innen und Institutionen

  • Centre for Integrative Omics Data Science (CIODS), Yenepoya (Deemed to be University), Mangalore, Karnataka, India.

Zitieren

APA

Madar, I. H., & Kammarambath, S. R. (2026). Past, present and future of nivolumab: new horizons in immuno-oncology. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1801874

Vancouver

Madar IH, Kammarambath SR. Past, present and future of nivolumab: new horizons in immuno-oncology. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1801874

BibTeX
@article{Madar2026,
  author = {Madar, Inamul Hasan and Kammarambath, Sreeshma Ravindran},
  title = {Past, present and future of nivolumab: new horizons in immuno-oncology},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1801874}
}
Kostenlos starten →